Literature DB >> 24813520

Steroids in pediatric eosinophilic esophagitis.

Emily M Contreras1, Sandeep K Gupta2.   

Abstract

Swallowed fluticasone and oral viscous budesonide are effective first-line therapies for eosinophilic esophagitis in children. Side effects are minimal without evidence of Cushing syndrome, as seen in treatment with systemic corticosteroids. New studies on alternative delivery systems and different corticosteroids (eg, ciclesonide) are encouraging. As knowledge of corticosteroids in eosinophilic esophagitis expands, newer questions continue to arise concerning dose, delivery, and choice of corticosteroids; long-term adverse effects; and maintenance therapies.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Budesonide; Children; Ciclesonide; Eosinophilic esophagitis; Fluticasone; Steroids; Topical steroids

Mesh:

Substances:

Year:  2014        PMID: 24813520      PMCID: PMC6662919          DOI: 10.1016/j.gtc.2014.02.008

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  4 in total

Review 1.  Recent discoveries and emerging therapeutics in eosinophilic esophagitis.

Authors:  Aakash Goyal; Edaire Cheng
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

2.  Translating new developments in eosinophilic esophagitis pathogenesis into clinical practice.

Authors:  Edaire Cheng
Journal:  Curr Treat Options Gastroenterol       Date:  2015-03

Review 3.  Eosinophilic esophagitis: From pathophysiology to treatment.

Authors:  Alessandra D'Alessandro; Dario Esposito; Marcella Pesce; Rosario Cuomo; Giovanni Domenico De Palma; Giovanni Sarnelli
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

Review 4.  Systematic review of histological remission criteria in eosinophilic esophagitis.

Authors:  Ransome Eke; Tong Li; Anna White; Tooba Tariq; Jonathan Markowitz; Andrey Lenov
Journal:  JGH Open       Date:  2018-06-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.